Dr. Neil Iyengar & Dr. Erika Hamilton – FirstLine TNBC: How TRO-Breast02 & ASCENT-03 Change the Game

Triple-negative breast cancer has entered a new era.

At ESMO 2025, TRO-Breast02 and ASCENT-03 delivered practice-shifting data — from rapid progressors to PD-L1–defined pathways and the growing role of TROP2-targeted ADCs.

Dr. Neil Iyengar and Dr. Erika Hamilton break down trial design differences, crossover implications, toxicity management, and how these results will shape first-line treatment decisions for TNBC.